Cost of sales increased over the prior year by $ 2.0 million due to the launch of Cinryze . In the comparative period in 2008 , the Company only had cost of sales related to Vancocin . As part of our October 2008 purchase of Lev , we acquired Cinryze inventory which was recorded at fair value in purchase accounting . This fair value of inventory will increase cost of sales until all purchased inventory is sold to SP / SD 's , which we expect to occur in the second half of 2009 .